{"slug":"pt-141-skin","verification":{"valid":true,"entries":2,"head":"b2c70b2cde4d81b9304b022921dbae0f1f9b28ad6c97c875f78d7b5086f33b9f"},"energy":{"passes":2,"tokens_in":12407,"tokens_out":3371,"tokens_total":15778,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"b2c70b2cde4d81b9304b022921dbae0f1f9b28ad6c97c875f78d7b5086f33b9f"},"provenance":[{"ts":"2026-06-30T01:08:05.963Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Skin\nSlug: pt-141-skin\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains ","response":"{\n  \"slug\": \"pt-141-skin\",\n  \"title\": \"PT-141 for Skin: Evidence Review of Effects and Observations\",\n  \"body\": \"## What's breaking down\\n\\nSkin tissue can face layers of degeneration where repair pathways lag behind daily wear, UV exposure, inflammation, or hormonal shifts. Pigment cells (melanocytes) may over- or under-respond, leading to uneven tone, spots, or loss of even coloration. Vascular and nerve signals in the skin also influence flushing or localized reactions. When breakdown outpaces natural repair, visible changes persist. PT-141 is discussed in this context because it engages melanocortin pathways that touch both central signaling and peripheral tissue responses.\\n\\n## Why PT-141 might help you\\n\\n1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nThe compound acts on melanocortin receptors including MC1R in skin cells. This interaction is studied for its role in melanocyte activity, which relates to pigment production and local tissue responses. If skin pigmentation or repair balance is your concern, the pathway offers a direct mechanistic link rather than symptom suppression alone.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\\n\\n## What the evidence actually shows\\n\\nHuman data come from clinical trials of bremelanotide for hypoactive sexual desire disorder. In those studies, focal hyperpigmentation occurred in about 1% of participants using up to 8 doses per month (human|source from trial reports). Daily use for 8 days led to focal hyperpigmentation in 38% of a smaller group, with additional changes after another 8 days (human). Flushing affected around 20% of users (human). No dedicated human trials examined PT-141 as a primary skin treatment.\\n\\nPreclinical work on related melanocor","tokens_in":12407,"tokens_out":3371,"cost":0,"prev":"genesis","hash":"271af65d54eef2a4e9796ede743dd906779adb04ac18e98db0fe650144a7f6ed"},{"ts":"2026-07-17T02:41:10.798Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-skin","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"271af65d54eef2a4e9796ede743dd906779adb04ac18e98db0fe650144a7f6ed","hash":"b2c70b2cde4d81b9304b022921dbae0f1f9b28ad6c97c875f78d7b5086f33b9f"}]}